摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5-bromo-2-chloro-pyrimidin-4-yl)-[2-(4-chloro-phenyl)-ethyl]-amine | 719313-25-4

中文名称
——
中文别名
——
英文名称
(5-bromo-2-chloro-pyrimidin-4-yl)-[2-(4-chloro-phenyl)-ethyl]-amine
英文别名
5-bromo-2-chloro-N-[2-(4-chlorophenyl)ethyl]pyrimidin-4-amine
(5-bromo-2-chloro-pyrimidin-4-yl)-[2-(4-chloro-phenyl)-ethyl]-amine化学式
CAS
719313-25-4
化学式
C12H10BrCl2N3
mdl
MFCD23250952
分子量
347.041
InChiKey
LQNJPYUMDDDULY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    515.8±50.0 °C(Predicted)
  • 密度:
    1.632±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    37.8
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Discovery of Orally Bioavailable Cathepsin S Inhibitors for the Reversal of Neuropathic Pain
    摘要:
    Cathepsin S inhibitors are well-known to be an attractive target as immunological therapeutic agents. Recently, Our gene expression analysis identified that cathepsin S inhibitors could also be effective for neuropathic pain. Herein, we describe the efficacy of selective cathepsin S inhibitors as antihyperalgesics in a model of neuropathic pain in rats after oral administration.
    DOI:
    10.1021/jm800839j
  • 作为产物:
    参考文献:
    名称:
    Discovery of Orally Bioavailable Cathepsin S Inhibitors for the Reversal of Neuropathic Pain
    摘要:
    Cathepsin S inhibitors are well-known to be an attractive target as immunological therapeutic agents. Recently, Our gene expression analysis identified that cathepsin S inhibitors could also be effective for neuropathic pain. Herein, we describe the efficacy of selective cathepsin S inhibitors as antihyperalgesics in a model of neuropathic pain in rats after oral administration.
    DOI:
    10.1021/jm800839j
点击查看最新优质反应信息

文献信息

  • Compound for the treatment of abnormal cell growth
    申请人:Pfizer Inc
    公开号:US20040220177A1
    公开(公告)日:2004-11-04
    The invention relates to compounds of the formula 1 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , n, A and B are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
    本发明涉及公式11的化合物,以及其药物可接受的盐、前药和溶剂化物,其中R1、R2、R3、R4、R5、n、A和B的定义如本文所述。本发明还涉及通过给予公式1的化合物治疗哺乳动物异常细胞生长的方法,并涉及用于治疗此类疾病的制药组合物,其中包含公式1的化合物。本发明还涉及制备公式1的化合物的方法。
查看更多